Notably, favorable outcomes were obtained, particularly for esophagogastric adenocarcinoma (NCT03812796), suggesting that domatinostat is currently one of the most promising HDAC inhibitors for clinical application [16]. This evidence concerns the gene HDAC9 and gastroesophageal junction adenocarcinoma.